TGFB1 and chronic kidney disease: However, targeting the TGF-β ligands or receptors that result in pan-TGF-β inhibition requires considerable caution in the long-term treatment of chronic diseases, such as CKD, as circumventing the potential side effects remains a significant hurdle to overcome.